Cargando…
Weight‐HbA1c‐insulin‐glucose model for describing disease progression of type 2 diabetes
A previous semi‐mechanistic model described changes in fasting serum insulin (FSI), fasting plasma glucose (FPG), and glycated hemoglobin (HbA1c) in patients with type 2 diabetic mellitus (T2DM) by modeling insulin sensitivity and β‐cell function. It was later suggested that change in body weight co...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4728293/ https://www.ncbi.nlm.nih.gov/pubmed/26844011 http://dx.doi.org/10.1002/psp4.12051 |
_version_ | 1782412081009524736 |
---|---|
author | Choy, S Kjellsson, MC Karlsson, MO de Winter, W |
author_facet | Choy, S Kjellsson, MC Karlsson, MO de Winter, W |
author_sort | Choy, S |
collection | PubMed |
description | A previous semi‐mechanistic model described changes in fasting serum insulin (FSI), fasting plasma glucose (FPG), and glycated hemoglobin (HbA1c) in patients with type 2 diabetic mellitus (T2DM) by modeling insulin sensitivity and β‐cell function. It was later suggested that change in body weight could affect insulin sensitivity, which this study evaluated in a population model to describe the disease progression of T2DM. Nonlinear mixed effects modeling was performed on data from 181 obese patients with newly diagnosed T2DM managed with diet and exercise for 67 weeks. Baseline β‐cell function and insulin sensitivity were 61% and 25% of normal, respectively. Management with diet and exercise (mean change in body weight = −4.1 kg) was associated with an increase of insulin sensitivity (30.1%) at the end of the study. Changes in insulin sensitivity were associated with a decrease of FPG (range, 7.8–7.3 mmol/L) and HbA1c (6.7–6.4%). Weight change as an effector on insulin sensitivity was successfully evaluated in a semi‐mechanistic population model. |
format | Online Article Text |
id | pubmed-4728293 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-47282932016-02-03 Weight‐HbA1c‐insulin‐glucose model for describing disease progression of type 2 diabetes Choy, S Kjellsson, MC Karlsson, MO de Winter, W CPT Pharmacometrics Syst Pharmacol Original Articles A previous semi‐mechanistic model described changes in fasting serum insulin (FSI), fasting plasma glucose (FPG), and glycated hemoglobin (HbA1c) in patients with type 2 diabetic mellitus (T2DM) by modeling insulin sensitivity and β‐cell function. It was later suggested that change in body weight could affect insulin sensitivity, which this study evaluated in a population model to describe the disease progression of T2DM. Nonlinear mixed effects modeling was performed on data from 181 obese patients with newly diagnosed T2DM managed with diet and exercise for 67 weeks. Baseline β‐cell function and insulin sensitivity were 61% and 25% of normal, respectively. Management with diet and exercise (mean change in body weight = −4.1 kg) was associated with an increase of insulin sensitivity (30.1%) at the end of the study. Changes in insulin sensitivity were associated with a decrease of FPG (range, 7.8–7.3 mmol/L) and HbA1c (6.7–6.4%). Weight change as an effector on insulin sensitivity was successfully evaluated in a semi‐mechanistic population model. John Wiley and Sons Inc. 2015-12-16 2016-01 /pmc/articles/PMC4728293/ /pubmed/26844011 http://dx.doi.org/10.1002/psp4.12051 Text en © 2015 The Authors CPT: Pharmacometrics & Systems Pharmacology published by Wiley Periodicals, Inc. on behalf of American Society for Clinical Pharmacology and Therapeutics This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial (http://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Original Articles Choy, S Kjellsson, MC Karlsson, MO de Winter, W Weight‐HbA1c‐insulin‐glucose model for describing disease progression of type 2 diabetes |
title | Weight‐HbA1c‐insulin‐glucose model for describing disease progression of type 2 diabetes |
title_full | Weight‐HbA1c‐insulin‐glucose model for describing disease progression of type 2 diabetes |
title_fullStr | Weight‐HbA1c‐insulin‐glucose model for describing disease progression of type 2 diabetes |
title_full_unstemmed | Weight‐HbA1c‐insulin‐glucose model for describing disease progression of type 2 diabetes |
title_short | Weight‐HbA1c‐insulin‐glucose model for describing disease progression of type 2 diabetes |
title_sort | weight‐hba1c‐insulin‐glucose model for describing disease progression of type 2 diabetes |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4728293/ https://www.ncbi.nlm.nih.gov/pubmed/26844011 http://dx.doi.org/10.1002/psp4.12051 |
work_keys_str_mv | AT choys weighthba1cinsulinglucosemodelfordescribingdiseaseprogressionoftype2diabetes AT kjellssonmc weighthba1cinsulinglucosemodelfordescribingdiseaseprogressionoftype2diabetes AT karlssonmo weighthba1cinsulinglucosemodelfordescribingdiseaseprogressionoftype2diabetes AT dewinterw weighthba1cinsulinglucosemodelfordescribingdiseaseprogressionoftype2diabetes |